- Trials with a EudraCT protocol (44,393)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (18,700)
44,393 result(s) found.
Displaying page 2,088 of 2,220.
| EudraCT Number: 2004-002979-16 | Sponsor Protocol Number: SPON UWCM 014 | Start Date*: 2004-11-12 |
| Sponsor Name:CARDIFF UNIVERSITY | ||
| Full Title: A Six-Week/Six-Week, Prospective, Randomised, Masked, Cross over, Primary Therapy Study comparing IOP Lowering Effects of Lumigan® and Xalatan® in Subjects with Primary Open Angle Glaucoma, Ocular... | ||
| Medical condition: Primary open-angle glaucoma, Ocular hypertension, Pseudoexfoliation glaucoma or Pigment dispersion | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2014-004944-37 | Sponsor Protocol Number: MK-3475-054-07 | Start Date*: 2015-09-22 | |||||||||||
| Sponsor Name:Merck Sharp & Dohme LLC, a Subsidiary of Merck & Co. Inc | |||||||||||||
| Full Title: Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double-blind Phase 3 trial o... | |||||||||||||
| Medical condition: Stage III melanoma (AJCC R0) with histologically confirmed cutaneous melanoma metastatic to lymph node, classified as (AJCC, 2010): Stage IIIA with metastasis > 1 mm; any Stage IIIB or IIIC (no in-... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Trial now transitioned) GB (GB - no longer in EU/EEA) DE (Trial now transitioned) PT (Trial now transitioned) ES (Ongoing) DK (Trial now transitioned) AT (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) FI (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2022-002323-35 | Sponsor Protocol Number: TAK-669-3001 | Start Date*: 2022-11-10 |
| Sponsor Name: Takeda Development Center Americas, Inc. | ||
| Full Title: A Multicenter, Open-label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Velaglucerase Alfa in Chinese Subjects With Type 1 Gaucher Disease | ||
| Medical condition: Type 1 Gaucher Disease | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
| Trial protocol: Outside EU/EEA | ||
| Trial results: View results | ||
| EudraCT Number: 2021-002570-54 | Sponsor Protocol Number: D8231C00001 | Start Date*: 2021-12-31 |
| Sponsor Name:AstraZeneca AB | ||
| Full Title: A Modular Phase II, Open-label, Multicentre Study to Assess AZD4573 Efficacy and Safety as Monotherapy or in Combination with Anti-cancer Agents in Patients with Relapsed/Refractory Peripheral T-ce... | ||
| Medical condition: - Relapsed/refractory Peripheral T-cell Lymphoma - Relapsed/refractory Classical Hodgkins Lymphoma | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FR (Completed) IT (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2021-006015-29 | Sponsor Protocol Number: ADA-IJZ-3001 | Start Date*: 2022-08-04 | |||||||||||
| Sponsor Name:Mylan Pharmaceuticals Inc., a Viatris Company | |||||||||||||
| Full Title: A Multicenter, Randomized, Blinded, Parallel Group, Interchangeability Study in Moderate to Severe Chronic Plaque Psoriasis evaluating Pharmacokinetics, Efficacy, Safety, and Immunogenicity Betwe... | |||||||||||||
| Medical condition: Moderate to Severe chronic plaque psoriasis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: CZ (Completed) EE (Completed) BG (Completed) PL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-001995-23 | Sponsor Protocol Number: NIBIT-MESO-1 | Start Date*: Information not available in EudraCT | |||||||||||
| Sponsor Name:FONDAZIONE NIBIT NETWORK ITALIANO PER LA BIOTERAPIA DEI TUMORI | |||||||||||||
| Full Title: A SINGLE ARM, PHASE II CLINICAL STUDY OF TREMELIMUMAB COMBINED WITH THE ANTI-PD-L1 MEDI4736 MONOCLONAL ANTIBODY IN UNRESECTABLE MALIGNANT MESOTHELIOMA SUBJECTS: NIBIT-MESO-1 STUDY | |||||||||||||
| Medical condition: UNRESECTABLE MALIGNANT MESOTHELIOMA | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-006514-37 | Sponsor Protocol Number: DOAC-CO | Start Date*: 2023-02-08 | |||||||||||
| Sponsor Name:Ente Ecclesiastico Ospedale Generale Regionale “F. Miulli” | |||||||||||||
| Full Title: Haemorrhagic risk of direct oral anticoagulants (DOACs) in patients undergoing oral surgery | |||||||||||||
| Medical condition: Patients on direct acting oral anticoagulants (DOACs) who are to undergo oral surgery. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2017-003170-13 | Sponsor Protocol Number: R1500-CL-1719 | Start Date*: 2018-03-15 | |||||||||||
| Sponsor Name:Regeneron Pharmaceuticals, Inc. | |||||||||||||
| Full Title: An open-label study to evaluate the long-term safety and efficacy of evinacumab in patients with homozygous familial hypercholesterolemia | |||||||||||||
| Medical condition: Homozygous familial hypercholesterolemia | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Completed) NO (Prematurely Ended) CZ (Completed) FR (Completed) GR (Completed) GB (GB - no longer in EU/EEA) AT (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-002960-42 | Sponsor Protocol Number: Yttrium-90-02 | Start Date*: 2017-11-15 | |||||||||||
| Sponsor Name:AZIENDA UNITÀ SANITARIA LOCALE DELLA ROMAGNA | |||||||||||||
| Full Title: 173/5000 Forse cercavi: Terapia radiometabolica recettoriale-mediata con [90Y-DOTA0-Tyr3]-octreotide (90Y-DOTATOC) nei tumori endocrini del tratto gastroenteropancreatico e bronchiale. (Yttrium-90... | |||||||||||||
| Medical condition: Patients with Somatostatin receptors Neoplasms | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-003764-27 | Sponsor Protocol Number: HS-20-677 | Start Date*: 2022-09-20 |
| Sponsor Name:Camurus AB | ||
| Full Title: A randomized, placebo-controlled, double-blind, multi-center trial to assess efficacy and safety of octreotide subcutaneous depot (CAM2029) in patients with symptomatic polycystic liver disease | ||
| Medical condition: Polycystic liver disease | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2021-003314-39 | Sponsor Protocol Number: 78934804CRD2001 | Start Date*: 2023-02-21 | |||||||||||
| Sponsor Name:Janssen-Cilag International NV | |||||||||||||
| Full Title: A Phase 2b Randomized, Double-blind, Active-and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy with Gusel... | |||||||||||||
| Medical condition: Moderately to Severely Active Crohn's Disease | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Trial now transitioned) ES (Ongoing) HU (Trial now transitioned) FR (Trial now transitioned) NL (Trial now transitioned) CZ (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) AT (Ongoing) PT (Trial now transitioned) BG (Trial now transitioned) IE (Completed) NO (Trial now transitioned) SI (Trial now transitioned) SE (Trial now transitioned) DK (Trial now transitioned) GR (Trial now transitioned) HR (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-001654-65 | Sponsor Protocol Number: PDY16967 | Start Date*: 2021-11-30 | |||||||||||
| Sponsor Name:Sanofi-Aventis Recherche & Developpement | |||||||||||||
| Full Title: A Phase 2a, open label, two-part study to evaluate the mechanism of action of itepekimab (anti-IL-33 mAb) on airway inflammation in patients with chronic obstructive pulmonary disease (COPD) | |||||||||||||
| Medical condition: Chronic Obstructive Pulmonary Disease | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Trial now transitioned) BE (Trial now transitioned) DK (Trial now transitioned) NL (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-003284-10 | Sponsor Protocol Number: EMN28/68284528MMY3005 | Start Date*: 2022-10-10 | |||||||||||
| Sponsor Name:Stichting European Myeloma Network (EMN) | |||||||||||||
| Full Title: A Phase 3 Randomized Study Comparing Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethas... | |||||||||||||
| Medical condition: Multiple Myeloma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Trial now transitioned) ES (Ongoing) NO (Trial now transitioned) BE (Trial now transitioned) NL (Ongoing) CZ (Trial now transitioned) GR (Trial now transitioned) FR (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2017-004706-18 | Sponsor Protocol Number: 269864 | Start Date*: 2018-05-07 |
| Sponsor Name:Akershus University Hospital | ||
| Full Title: Long acting naltrexone for opioid addiction: the importance of mental, physical and societal factors for sustained abstinence and recovery (NaltRec) | ||
| Medical condition: Opioid addiction | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NO (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2018-000334-35 | Sponsor Protocol Number: 1368-0017 | Start Date*: 2018-10-22 | |||||||||||
| Sponsor Name:SCS Boehringer Ingelheim Comm. V | |||||||||||||
| Full Title: An open label, long term safety trial of BI 655130 treatment in patients with moderate to severely active ulcerative colitis who have completed previous BI 655130 trials | |||||||||||||
| Medical condition: Moderate-to-severely active ulcerative colitis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) AT (Prematurely Ended) ES (Ongoing) GB (GB - no longer in EU/EEA) DE (Completed) NL (Prematurely Ended) PL (Completed) NO (Completed) HU (Prematurely Ended) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-005097-19 | Sponsor Protocol Number: EVOLVD | Start Date*: 2019-01-23 |
| Sponsor Name:Oslo University Hospital | ||
| Full Title: Cholesterol lowering with EVOLocumab to prevent cardiac allograft Vasculopathy in De-novo heart transplant recipients | ||
| Medical condition: Cardiac allograft vasculopathy in de-novo heart transplant recipients | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: NO (Completed) DK (Completed) FI (Completed) SE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2018-000620-34 | Sponsor Protocol Number: Imatinib-MS | Start Date*: 2018-04-24 | ||||||||||||||||
| Sponsor Name:Department of Clinical Neuroscience, Karolinska Institutet | ||||||||||||||||||
| Full Title: Imatinib for Multiple Sclerosis (MS) Relapses - a Phase II, Randomised Study | ||||||||||||||||||
| Medical condition: Patients with clinically definite Multiple Sclerosis (MS) according to the McDonald Criteria, or possible MS (also named clinically isolated syndrome-CIS, as a first manifestation of MS, where ther... | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults | Gender: Male, Female | |||||||||||||||||
| Trial protocol: SE (Prematurely Ended) NO (Prematurely Ended) DE (Prematurely Ended) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2018-001165-16 | Sponsor Protocol Number: TITAN-001 | Start Date*: 2018-11-28 | |||||||||||
| Sponsor Name:Department of infectious Diseases, Aarhus University Hospital | |||||||||||||
| Full Title: Combining a TLR9 agonist with broadly neutralizing antibodies for reservoir reduction and immunological control of HIV infection: An investigator-initiated randomized, placebo-controlled, phase IIa... | |||||||||||||
| Medical condition: HIV infection | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Completed) NO (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-004805-17 | Sponsor Protocol Number: AC-061A303 | Start Date*: 2017-07-12 | ||||||||||||||||||||||||||
| Sponsor Name:Actelion Pharmaceuticals Ltd. | ||||||||||||||||||||||||||||
| Full Title: A prospective, multicenter study to investigate the pharmacokinetics, safety, and efficacy of cadazolid versus vancomycin in pediatric subjects with Clostridium difficile-associated diarrhea. | ||||||||||||||||||||||||||||
| Medical condition: Clostridium difficile-associated diarrhea (CDAD) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: BE (Completed) HU (Completed) IT (Completed) ES (Completed) | ||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||
| EudraCT Number: 2020-002732-75 | Sponsor Protocol Number: MSC-ACLrep | Start Date*: 2021-02-01 | |||||||||||
| Sponsor Name:Alexander IV sp. Partnership Ortopedika Surgery Specialistic Center | |||||||||||||
| Full Title: The use of mesenchymal stem cells from the bone marrow stroma for reconstruction of the anterior cruciate ligament | |||||||||||||
| Medical condition: Rupture of the anterior cruciate ligament in the knee | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: PL (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.